ArticleAntimicrobial agents and chemotherapy2009
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Active site loops of membrane-anchored metallo-β-lactamases from environmental bacteria determine cephalosporinase activity.Antimicrobial agents and chemotherapy · 2025Article
- Genomic Insights into Emerging Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- A case of hospital-acquired pneumonia associated with Chryseobacterium indologenes infection in a patient with HIV infection and review of the literature.AIDS research and therapy · 2025Review
- Novel Antibiotic Resistance Genes Identified by Functional Gene Library Screening inInternational journal of molecular sciences · 2023Article
- Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR)Frontiers in cellular and infection microbiology · 2023Article
- Article
- Chryseobacterium gleum in a man with prostatectomy in Senegal: a case report and review of the literature.Journal of medical case reports · 2017Review
- Chryseobacterium indologenes: an emerging infection in the USA.BMJ case reports · 2016Review
- Whole genome sequencing uncovers a novel IND-16 metallo-β-lactamase from an extensively drug-resistantGut pathogens · 2016Article
- Biochemical Characterization of CPS-1, a Subclass B3 Metallo-β-Lactamase from a Chryseobacterium piscium Soil Isolate.Antimicrobial agents and chemotherapy · 2015Article
- A case of septicemia due to Chyresobacterium indologenes producing blaNDM-1.Avicenna journal of medicine · 2014Article
- Chryseobacterium indologenes in a woman with acute leukemia in Senegal: a case report.Journal of medical case reports · 2014Article
- Profile and multidrug resistance determinants of Chryseobacterium indologenes from seawater and marine fauna.World journal of microbiology & biotechnology · 2013Article
- Characterization of CIA-1, an Ambler class A extended-spectrum β-lactamase from Chryseobacterium indologenes.Antimicrobial agents and chemotherapy · 2012Article
- Draft genome sequence of Chryseobacterium limigenitum SUR2Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Chryseobacterium and other genera belonging to the family Flavobacteriaceae include organisms that can behave as human pathogens and are known to cause different kinds of infections. Several species of Flavobacteriaceae, including Chryseobacterium indologenes, are naturally resistant to beta-lactam antibiotics (including carbapenems), due to the production of a resident metallo-beta-lactamase. Although C. indologenes presently constitutes a limited clinical threat, the incidence of infections caused by this organism is increasing in some settings, where isolates that exhibit multidrug resistance phenotypes (including resistance to aminoglycosides and quinolones) have been detected. Here, we report the identification and characterization of a new IND-type variant from a C. indologenes isolate from Burkina Faso that is resistant to beta-lactams and aminoglycosides. The levels of sequence identity of the new variant to other IND-type metallo-beta-lactamases range between 72 and 90% (for IND-4 and IND-5, respectively). The purified enzyme exhibited N-terminal heterogeneity and a posttranslational modification consisting of the presence of a pyroglutamate residue at the N terminus. IND-6 shows a broad substrate profile, with overall higher turnover rates than IND-5 and higher activities than IND-2 and IND-5 against ceftazidime and cefepime.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.